MSD\'s Keytrudachemo combo scores firstline FDA approval in NSC lung cancer

MSD's Keytruda/chemo combo scores first-line FDA approval in NSC lung cancer

06:19 EDT 1 Nov 2018 | Pharmafile

MSD’s blockbuster anti-PD-1 immunotherapy has secured another FDA approval, it has emerged, in combination with carboplatin and either paclitaxel or nab-paclitaxel chemotherapy, for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC).

The US regulator’s decision was based on Phase 3 data which demonstrated significant overall survival benefit of Keytruda regardless of the tumour PD-L1 expression status of a patient, with it found to reduce the risk of death by 36% compared to chemotherapy alone.

MSD\'s Keytrudachemo combo scores firstline FDA approval in NSC lung cancer

MSD's Keytruda/chemo combo scores first-line FDA approval in NSC lung cancer

MSD’s blockbuster anti-PD-1 immunotherapy has secured another FDA approval, it has emerged, in combination with carboplatin and either paclitaxel or nab-paclitaxel chemotherapy, for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC).

More From BioPortfolio on "MSD's Keytruda/chemo combo scores first-line FDA approval in NSC lung cancer"